Evidence for the locations of distinct steroid and Vinca alkaloid interaction domains within the murine mdr1b P-glycoprotein

Molecular Pharmacology

Volumn 62, Issue 5, 2002, Pages 1238-1248

  Gruol, Donald J ^a   King, Miranda N ^a   Kuehne, Martin E ^b  

^a SIDNEY KIMMEL CANCER CENTER   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; STEROID; VINCA ALKALOID;

AMINO ACID METABOLISM; ANIMAL CELL; ARTICLE; CELL COMPARTMENTALIZATION; COMPLEX FORMATION; DRUG BINDING; GENE MUTATION; HYDROPHOBICITY; MOLECULAR INTERACTION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; MICE; MOLECULAR SEQUENCE DATA; MUTATION; P-GLYCOPROTEIN; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; STEROIDS; VINBLASTINE;

EID: 0036839818     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.62.5.1238     Document Type: Article

References (43)

1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, and Gottesman MM (1999) Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398.
2. Ayesh S, Shao Y-M, and Stein WD (1996) Co-operative, competitive and noncompetitive interactions between modulators of P-glycoprotein. Biochim Biophys Acta 1316:8-18.
3. Beaudet L, Urbatsch IL, and Gros P (1998) Mutations in the nucleotide-binding sites of P-glycoprotein that affect substrate specificity modulate substrate-induced adenosine triphosphatase activity. Biochemistry 37:9073-9082.
4. Borman LS, Bornmann WG, and Kuehne ME (1993) Modulation of drug cytotoxicity in wild-type and multidrug-resistant tumor cells by stereoisomeric series of C-20′-vinblastine congeners that lack antimicrotubule activity. Cancer Chemother Pharmacol 31:343-349.
5. Bourgeois S, Gruol DJ, Newby RF, and Rajah FM (1993) Expression of an mdr gene is associated with a new form of resistance to dexamethasone-induced apoptosis. Mol Endocrinol 7:840-851.
6. Bruggemann EP, Currier SJ, Gottesman MM, and Pastan I (1992) Characterization of the azidopine and vinblastine binding site of P-glycoprotein. J Biol Chem 267:21020-21026.
7. Bruggemann EP, Germann UA, Gottesman MM, and Pastan I (1989) Two different regions ofphosphoglycoprotein are photoaffinity labeled by azidopine. J Biol Chem 264:15483-15488.
8. Chen CJ, Clark D, Ueda K, Pastan I, Gottesman MM, and Roninson IB (1990) Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem 265:506-514.
9. Chen Y, Pant AC, and Simon SM (2001) P-glycoprotein does not reduce substrate concentration from the extracellular leaflet of the plasma membrane in living cells. Cancer Res 61:7763-7769.
10. Demmer A, Thole H, Kubesch P, Brandt T, Raida M, Fislage R, and Tummler B (1997) Localization of the iodomycin binding site in hamster P-glycoprotein. J Biol Chem 272:20913-20919.
11. Dey S, Ramachandra M, Pastan I, Gottesman MM, and Ambudkar SV (1997) Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci USA 94:10594-10599.
12. Eytan GD and Kuchel PW (1999) Mechanism of action of P-glycoprotein in relation to passive membrane permeation. Int Rev Cytol 190:175-250.
13. 3H]vinblastine binding to P-glycoprotein of MCF-7 ADR cells by dexniguldipine. Biochem Pharmacol 49:1851-1861.
14. Gottesman MM, Fojo T, and Bates SE (2002) Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2:48-58.
15. Greenberger LM (1993) Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domains 6 and 12. J Biol Chem 268:11417-11425.
16. 1-adrenergic receptor and the calcium channel bind to a common domain in P-glycoprotein. J Biol Chem 265:4394-4401.
17. Gruol DJ, Bernd J, Phippard AE, Ojima I, and Bernacki RJ (2001) The use of a novel taxane-based P-glycoprotein inhibitor to identify mutations that alter the interaction of the protein with paclitaxel. Mol Pharmacol 60:104-113.
18. Gruol DJ and Bourgeois S (1997) Chemosensitizing steroids: Glucocorticoid receptor agonists capable of inhibiting P-glycoprotein function. Cancer Res 57:720-727.
19. Gruol DJ, Vo QD, and Zee MC (1999) Profound differences in the transport of steroids by two mouse P-glycoproteins. Biochem Pharmacol 58:1191-1199.
20. Gruol DJ, Zee MC, Trotter J, and Bourgeois S (1994) Reversal of multidrug resistance by RU486. Cancer Res 54:3088-3091.
21. Harris AW, Bankhurst AD, Mason S, and Warner NL (1973) Differentiated functions expressed by cultured mouse lymphoma cells. II. Theta antigen, surface immunoglobulin and a receptor on cells of a thymoma cell line. J Immunol 110:431-438.
22. Higgins CF and Gottesman MM (1992) Is the multidrug transporter a flippase? Trends Biochem Sci 17:18-21.
23. Isenberg B, Thole H, Tummler B, and Demmer A (2001) Identification and localization of three photobinding sites of iodoarylazidoprazosin in hamster P-glycoprotein. Eur J Biochem 268:2629-2634.
24. Kolchinsky A and Roninson IB (1997) Drug resistance conferred by MDR1 expression in spheroids formed by glioblastoma cell lines. Anticancer Res 17:3321-3377.
25. Loo TW and Clarke DM (1999) Determining the structure and mechanism of the human multidrug resistance P-glycoprotein using cysteine-scanning mutagenesis and thiol-modification techniques. Biochim Biophys Acta 1461:315-325.
26. Loo TW and Clarke DM (2000) The Packing of the Transmembrane Segments of Human Multidrug Resistance P-glycoprotein Is Revealed by Disulfide Cross-linking Analysis. J Biol Chem 275:5253-5256.
27. Loo TW and Clarke DM (2001) Defining the drug-binding site in the human multidrug resistance P-glycoprotein using a methanethiosulfonate analog of verapamil, MTS- verapamil. J Biol Chem 276:14972-14979.
28. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, and Callaghan R (2000) Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58:624-632.
29. Morris DI, Greenberger LM, Bruggemann EP, Cardarelli C, Gottesman MM, Pastan I, and Seamon KB (1995) Localization of the forskolin labeling sites to both halves of P-glycoprotein: Similarity of the sites labeled by forskolin and prazosin. Mol Pharmacol 46:329-337.
30. Pascaud C, Garrigos M, and Orlowski S (1998) Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents. Biochem J 333:351-358.
31. Raviv Y, Pollard HB, Bruggemann EP, Pastan I, and Gottesman MM (1990) Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J Biol Chem 265:3975-3980.
32. Raymond M and Gros P (1989) Mammalian multidrug-resistance gene: Correlation of exon organization with structural domains and duplication of an ancestral gene. Proc Natl Acad Sci USA 86:6488-6492.
33. Rosenberg MF, Velarde G, Ford RC, Martin C, Berridge G, Kerr ID, Callaghan R, Schmidlin A, Wooding C, Linton KJ, et al. (2001) Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle. EMBO (Eur Mol Biol Organ) J 20:5615-5625.
34. Scala S, Akhmed N, Rao US, Paull K, Lan LB, Dickstein B, Lee JS, Elgemeie GH, Stein WD, and Bates SE (1997) P-glycoprotein substrates and antagonists cluster into two distinct groups. Mol Pharmacol 51:1024-1033.
35. Schumacher MA, Miller MC, Grkovic S, Brown MH, Skurray RA, and Brennan RG (2001) Structural mechanisms of QacR induction and multidrug recognition. Science (Wash DC) 294:2158-2163.
36. Shapiro AB, Fox K, Lam P, and Ling V (1999) Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur J Biochem 259:841-850.
37. Shapiro AB and Ling V (1998) Transport of LDS-751 from the cytoplasmic leaflet of the plasma membrane by the rhodamine-123-selective site of P-glycoprotein. Eur J Biochem 254:181-188.
38. Spoelstra EC, Westerhoff HV, Pinedo HM, Dekker H, and Lankelma J (1994) The multidrug-resistance-reverser verapamil interferes with cellular P-glycoprotein-mediated pumping of daunorubicin as a non-competing substrate. Eur J Biochem 221:363-373.
39. Tamai I and Safa AR (1991) Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. J Biol Chem 266:16796-16800.
40. van Veen HW and Konings WN (1997) Multidrug transporters from bacteria to man: Similarities in structure and function. Semin Cancer Biol 8:183-191.
41. Vo QD and Gruol DJ (1999) Identification of P-glycoprotein mutations causing a loss of steroid recognition and transport. J Biol Chem 274:20318-20327.
42. Wu Q, Bounaud PY, Kuduk SD, Yang CP, Ojima I, Horwitz SB, and Orr GA (1998) Identification of the domains of photoincorporation of the 3′-and 7-benzophenone analogues of Taxol in the carboxyl-terminal half of murine mdr1b P-glycoprotein. Biochemistry 37:11272-11279.
43. Zhang X, Collins KI, and Greenberger LM (1995) Functional evidence that transmembrane 12 and the loop between transmembrane 11 and 12 form part of the drug-binding domain in P-glycoprotein encoded by MDR1. JBiol Chem 270:5441-5448.